A phase II study of weekly docetaxel (T), estramustine (E), and celecoxib (C) in patients with hormone refractory prostate cancer (HRPC).

被引：0
|
作者：
Mellado, B
Font, A
Carles, J
Catalán, G
Larriba, JLG
Gallardo, E
Fernández, LA
Nogué, M
Lianes, P
Del Alba, AG
机构：
[1] Hosp Clin Barcelona, Barcelona, Spain
[2] Univ Barcelona, Hosp Germans Trias & Pujol, Barcelona, Spain
[3] Hosp del Mar, Barcelona, Spain
[4] Hosp Son Liatzer, Islas Baleares, Spain
[5] Hosp Clin San Carlos, Madrid, Spain
[6] Corp Sanitaria Parc Tauli, Barcelona, Spain
[7] Hosp Terrassa, Barcelona, Spain
[8] Hosp Gen Vic, Barcelona, Spain
[9] Hosp Mataro, Barcelona, Spain
[10] Hosp Son Dureta, Islas Baleares, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：434S / 434S
页数：1
相关论文
共 50 条
  • [31] A phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naive patients with metastatic hormone refractory prostate cancer (HRPC)
    Breitz, H. B.
    Roman, L. A.
    Karlov, P. A.
    Cheporov, S. V.
    Lopatkin, N. D.
    Baker, G. S.
    Karlin, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel
    Chi, K. N.
    Beardsley, E. K.
    Venner, P. M.
    Eigl, B. J.
    Hotte, S. J.
    Ko, Y.
    Saad, F.
    Winquist, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] Randomized phase IIb trial comparing two schedules of docetaxel (D) plus estramustine (E) for metastatic hormone refractory prostate cancer (HRPC).
    Birch, R
    Kalman, L
    Holt, L
    Graham, B
    Wheeler, B
    Schwartzberg, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 412S - 412S
  • [34] Dose-finding study of weekly docetaxel plus estramustine in patients with hormone-refractory metastatic prostate cancer
    Coccaro, M
    Tartarone, A
    Romano, G
    Ardito, R
    Di Renzo, N
    TUMORI, 2005, 91 (04) : 314 - 316
  • [35] Weekly docetaxel and bortezomib in the treatment of patients with advanced hormone refractory prostate cancer (HRPC): A Minnie Pearl Cancer Research Network phase II trial.
    Meluch, AA
    Spigel, DS
    Greco, FA
    Barton, JH
    Messina, G
    Gould, B
    Rovito, MA
    Hainsworth, JD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 436S - 436S
  • [36] Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer
    Eymard, J.-C.
    Priou, F.
    Zannetti, A.
    Ravaud, A.
    Lepille, D.
    Kerbrat, P.
    Gomez, P.
    Paule, B.
    Genet, D.
    Herait, P.
    Ecstein-Fraisse, E.
    Joly, F.
    ANNALS OF ONCOLOGY, 2007, 18 (06) : 1064 - 1070
  • [37] Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study
    Font, A
    Murias, A
    Arroyo, FRG
    Martin, C
    Areal, J
    Sanchez, JJ
    Santiago, JA
    Constenla, M
    Saladie, JM
    Rosell, R
    ANNALS OF ONCOLOGY, 2005, 16 (03) : 419 - 424
  • [38] Bis docetaxel (D) ± estramustine (E) as first line chemotherapy for patients (PTS) with hormone-refractory advanced prostate cancer (HRPC).: A multicentric Italian phase II randomized trial
    Caffo, O.
    Sava, T.
    Comploj, E.
    Zustovich, F.
    Mansueto, G.
    Segati, R.
    Sacco, C.
    Perin, A.
    Frisinghelli, M.
    Valduga, F.
    Galligioni, E.
    ANNALS OF ONCOLOGY, 2006, 17 : XI80 - XI80
  • [39] Weekly Docetaxel and Pegylated liposomal doxorubicin (PLD) in metastatic hormone refractory prostate cancer (HRPC)
    Pacilio, G.
    De Filippis, L.
    Simeon, D.
    De Domenico, R.
    ANNALS OF ONCOLOGY, 2005, 16 : 154 - 154
  • [40] Phase II study of single agent gemcitabine in patients with hormone refractory prostate cancer (HRPC).
    Nilsson, S
    Holmberg, M
    Ljung, G
    Pettersson-Skjold, D
    Blom, R
    Ullén, A
    Westberg, R
    Nilsson, I
    Lennernas, B
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 432S - 432S
12345